Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionNorthwestern Mutual Wealth Management Co
Latest Disclosed Ownership916 shares
Latest Disclosed Value $ 303,078
Northwestern Mutual Wealth Management Co reports 57.66% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 7, 2026 - Northwestern Mutual Wealth Management Co filed a 13F-HR form disclosing ownership of 916 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $261,701 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on February 10, 2026 disclosing 581 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 57.66% during the quarter. The current value of the position is $238,618 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 916 335 57.66 303 31.17 0.0002
2026-02-10 2025-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 581 14 2.47 231 -10.47 0.0001
2026-02-05 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,234 5,667 703 0.0004
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 567 71 14.31 259 60.25 0.0002
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 496 -29 -5.52 162 14.18 0.0001
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 525 49 10.29 142 25.89 0.0001
2025-02-11 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 476 -47 -8.99 112 -21.68 0.0001
2024-11-12 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 523 -73 -12.25 144 -0.69 0.0001
2024-08-16 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 596 250 72.25 145 182.35 0.0001
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 346 -180 -34.22 52 -49.00 0.0001
2024-02-13 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 526 46 9.58 101 17.65 0.0001
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 480 45 10.34 85 3.66 0.0001
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 435 -96 -18.08 83 -22.64 0.0001
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 531 158 42.36 106 20.45 0.0001
2023-02-21 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 373 139 59.40 89 87.23 0.0001
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 234 -166 -41.50 47 -20.34 0.0001
2022-08-04 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 400 -206 -33.99 59 -39.80 0.0001
2022-05-09 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 606 5 0.83 98 -3.92 0.0002
2022-02-03 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 601 0 0.00 102 -10.53 0.0002
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 601 0 0.00 114 11.76 0.0002
2021-08-13 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 601 231 62.43 102 96.15 0.0002
2021-05-14 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 370 41 12.46 52 20.93 0.0001
2021-02-12 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 329 21 6.82 43 -4.44 0.0001
2020-11-13 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 308 33 12.00 45 9.76 0.0001
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 275 0 0.00 41 36.67 0.0001
2020-05-08 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 275 -151 -35.45 30 -38.78 0.0001
2020-02-13 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 426 -514 -54.68 49 -35.53 0.0002
2019-11-12 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 940 158 20.20 76 33.33 0.0003
2019-08-12 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 782 81 11.55 57 -13.64 0.0002
2019-05-10 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 701 511 268.95 66 371.43 0.0003
2019-02-12 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 190 100 111.11 14 75.00 0.0001
2018-11-01 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 90 90 8 0.0000
2017-02-15 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -42 -100.00 0 -100.00
2016-11-14 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 42 35 500.00 2 0.0000
2016-08-29 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7 7 0 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.